Allergan PLC. (AGN) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. decreased its stake in shares of Allergan PLC. (NYSE:AGN) by 2.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 546,700 shares of the company’s stock after selling 16,564 shares during the period. Principal Financial Group Inc. owned approximately 0.16% of Allergan PLC. worth $112,046,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Howard Hughes Medical Institute acquired a new position in Allergan PLC. during the 2nd quarter valued at about $103,000. Cable Hill Partners LLC increased its stake in Allergan PLC. by 255.2% during the 3rd quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock valued at $106,000 after buying an additional 370 shares during the period. Rockefeller Financial Services Inc. increased its stake in Allergan PLC. by 283.7% during the 3rd quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock valued at $111,000 after buying an additional 400 shares during the period. Jacobi Capital Management LLC increased its stake in Allergan PLC. by 4.9% during the 1st quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after buying an additional 22 shares during the period. Finally, Massey Quick & Co. LLC increased its stake in Allergan PLC. by 334.8% during the 2nd quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock valued at $122,000 after buying an additional 385 shares during the period. 82.14% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This article was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.chaffeybreeze.com/2017/11/12/allergan-plc-agn-shares-sold-by-principal-financial-group-inc.html.

Shares of Allergan PLC. (NYSE:AGN) opened at €172.21 ($200.24) on Friday. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40. The company has a market cap of $57,274.12, a P/E ratio of 11.17, a P/E/G ratio of 1.09 and a beta of 1.13. Allergan PLC. has a fifty-two week low of €169.64 ($197.26) and a fifty-two week high of €256.80 ($298.60).

Allergan PLC. (NYSE:AGN) last posted its quarterly earnings results on Wednesday, November 1st. The company reported €4.15 ($4.83) EPS for the quarter, topping the consensus estimate of €4.06 ($4.72) by €0.09 ($0.10). The business had revenue of €4.03 billion during the quarter, compared to analysts’ expectations of €4.04 billion. Allergan PLC. had a negative net margin of 47.27% and a positive return on equity of 8.00%. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period last year, the company posted $3.32 earnings per share. analysts anticipate that Allergan PLC. will post 16.28 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Friday, November 17th will be issued a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a dividend yield of 1.63%. The ex-dividend date is Thursday, November 16th. Allergan PLC.’s dividend payout ratio is currently -12.44%.

Allergan PLC. announced that its board has approved a stock repurchase program on Monday, September 25th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the company to repurchase up to 2.8% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its stock is undervalued.

Several equities analysts have recently issued reports on the stock. Royal Bank Of Canada set a $284.00 price objective on shares of Allergan PLC. and gave the stock a “buy” rating in a research note on Sunday, July 16th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $273.00 price objective (up previously from $265.00) on shares of Allergan PLC. in a research note on Monday, July 17th. Credit Suisse Group reaffirmed an “outperform” rating and issued a $286.00 price objective (up previously from $274.00) on shares of Allergan PLC. in a research note on Thursday, July 20th. Mizuho reaffirmed a “buy” rating and issued a $267.00 price objective on shares of Allergan PLC. in a research note on Wednesday, August 2nd. Finally, Wells Fargo & Company lifted their price objective on shares of Allergan PLC. to $278.00 and gave the stock an “outperform” rating in a research note on Thursday, August 3rd. One analyst has rated the stock with a sell rating, eleven have given a hold rating and twelve have issued a buy rating to the company’s stock. Allergan PLC. has an average rating of “Hold” and an average target price of €246.73 ($286.90).

About Allergan PLC.

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women’s health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer’s disease.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply